Xiong C, Levis R, Shen P, Schlesinger S, Rice CM, Huang HV. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science. 1989;243:1188–91.
Google Scholar
Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol. 1993;67:6439–46.
Google Scholar
Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki forest virus replicon. Bio/Technol. 1991;9:1356–61.
Lundstrom K. Self-amplifying RNA viruses as RNA vaccines. Int J Mol Sci. 2020;21:5130.
Google Scholar
Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines. 2021;9:97.
Google Scholar
Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26:446–55.
Google Scholar
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N. Engl J Med. 2020;383:1920–31.
Google Scholar
Borah P, Deb PK, Al-Shar’i NA, Dahabiyeh LA, Venugopala KN, Singh V, et al. Perspectives on RNA vaccine candidates for COVID-19. Front Mol Biosci. 2021;8:30.
Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest. 2010;120:3234–41.
Google Scholar
Slovin SF, Kehoe M, Durso R, Fernandez C, Olson W, Gao JP, et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2013;31:943–9.
Google Scholar
Wecker M, Gilbert P, Russell N, Hural J, Allen M, Pensiero M, et al. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccin Immunol CVI. 2012;19:1651–60.
Google Scholar
Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine. 2009;28:484–93.
Google Scholar
Drake CG, Johnson ML, Spira AI, Manji GA, Carbone DP, Henick BS, et al. Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies. J Clin Oncol. 2020;38:3137–3137.
Low JG. A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults | medRxiv. https://www.medrxiv.org/content/10.1101/2021.07.01.21259831v1 (accessed 22 Oct 2021).
Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, et al. Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial. Social Science Research Network: Rochester, NY, 2021. https://doi.org/10.2139/ssrn.3859294.
Baronti L, Karlsson H, Marušič M, Petzold K. A guide to large-scale RNA sample preparation. Anal Bioanal Chem. 2018;410:3239–52.
Google Scholar
Walker SE & Lorsch J. Chapter nineteen – RNA purification – precipitation methods. In: Lorsch J (ed). Methods in Enzymology. Academic Press, 2013, pp 337–43.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl J Med. 2020;383:2603–15.
Google Scholar
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl J Med. 2021;384:403–16.
Google Scholar
Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325:2201–2.
Google Scholar
van de Berg D, Kis Z, Behmer CF, Samnuan K, Blakney AK, Kontoravdi C, et al. Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. NPJ Vaccines. 2021;6:65.
Google Scholar
Kis Z, Kontoravdi C, Shattock R, Shah N. Resources, production scales and time required for producing RNA vaccines for the global pandemic demand. Vaccines. 2020;9:3.
Google Scholar
Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA. 2012;109:14604–9.
Google Scholar
Rossi A, Dupaty L, Aillot L, Zhang L, Gallien C, Hallek M, et al. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Sci Rep. 2019;9:3631.
Google Scholar
Mendonça SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. Npj Vaccines. 2021;6:1–14.
In a major setback, Merck to stop developing its two Covid-19 vaccines and focus on therapies. https://www.statnews.com/2021/01/25/in-a-major-setback-merck-to-stop-developing-its-two-covid-19-vaccines-and-focus-on-therapies/.
Fathi A, Dahlke C, Addo MM. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Hum Vaccines Immunother. 2019;15:2269–85.
CDC.gov. Ebola Vaccine: Information about Ervebo. https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html#:~:text=Ervebo%C2%AE%20(Ebola%20Zaire%20Vaccine,as%20a%20single%20dose%20administration.
Li Y, Su Z, Zhao W, Zhang X, Momin N, Zhang C, et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nat Cancer. 2020;1:882–93.
Google Scholar
Ni P, Cheng Kao C. Non-encapsidation activities of the capsid proteins of positive-strand RNA viruses. Virology. 2013;446:123–32.
Google Scholar
Garmashova N, Gorchakov R, Frolova E, Frolov I. Sindbis virus nonstructural protein nsP2 is cytotoxic and inhibits cellular transcription. J Virol. 2006;80:5686–96.
Google Scholar
Gorchakov R, Frolova E, Frolov I. Inhibition of transcription and translation in Sindbis virus-infected cells. J Virol. 2005;79:9397–409.
Google Scholar
Bhalla N, Sun C, Metthew Lam LK, Gardner CL, Ryman KD, Klimstra WB. Host translation shutoff mediated by non-structural protein 2 is a critical factor in the antiviral state resistance of Venezuelan equine encephalitis virus. Virology. 2016;496:147–65.
Google Scholar
Ventoso I, Sanz MA, Molina S, Berlanga JJ, Carrasco L, Esteban M. Translational resistance of late alphavirus mRNA to eIF2α phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev. 2006;20:87–100.
Google Scholar
Barry G, Breakwell L, Fragkoudis R, Attarzadeh-Yazdi G, Rodriguez-Andres J, Kohl A, et al. PKR acts early in infection to suppress Semliki Forest virus production and strongly enhances the type I interferon response. J Gen Virol. 2009;90:1382–91.
Google Scholar
Pichlmair A, Reise Sousa C. Innate recognition of viruses. Immunity. 2007;27:370–83.
Google Scholar
Translate Bio’s mRNA fails to improve lung function in cystic fibrosis patients. Httpswwwfiercebiotechcombiotechtranslate-Bio–Mrna-Fails–Improve-Lung-Funct.-Cyst.-Fibros.-Patients. https://www.fiercebiotech.com/biotech/translate-bio-s-mrna-fails-to-improve-lung-function-cystic-fibrosis-patients.
Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165–75.
Google Scholar
Suthar MS, Shabman R, Madric K, Lambeth C, Heise MT. Identification of adult mouse neurovirulence determinants of the Sindbis virus strain AR86. J Virol. 2005;79:4219–28.
Google Scholar
Simmons JD, Wollish AC, Heise MT. A determinant of Sindbis virus neurovirulence enables efficient disruption of Jak/STAT signaling. J Virol. 2010;84:11429–39.
Google Scholar
Kumar A, Mamidi P, Das I, Nayak TK, Kumar S, Chhatai J, et al. A novel 2006 Indian outbreak strain of Chikungunya virus exhibits different pattern of infection as compared to prototype strain. PLoS ONE. 2014;9:e85714.
Google Scholar
Nayak TK, Mamidi P, Kumar A, Singh LPK, Sahoo SS, Chattopadhyay S, et al. Regulation of viral replication, apoptosis and pro-inflammatory responses by 17-AAG during Chikungunya virus infection in macrophages. Viruses. 2017;9:3.
Trobaugh DW, Sun C, Bhalla N, Gardner CL, Dunn MD, Klimstra WB. Cooperativity between the 3’ untranslated region microRNA binding sites is critical for the virulence of eastern equine encephalitis virus. PLOS Pathog. 2019;15:e1007867.
Google Scholar
Rangel MV, Stapleford KA. Alphavirus virulence determinants. Pathogens. 2021;10:981.
Google Scholar
Jayabalan AK, Adivarahan S, Koppula A, Abraham R, Batish M, Zenklusen D, et al. Stress granule formation, disassembly, and composition are regulated by alphavirus ADP-ribosylhydrolase activity. Proc Natl Acad Sci USA. 2021;118. https://doi.org/10.1073/pnas.2021719118.
Cappuccio L, Maisse C. Infection of mammals and mosquitoes by alphaviruses: involvement of cell death. Cells. 2020;9:2612.
Google Scholar
Munz C. Autophagy proteins influence endocytosis for MHC restricted antigen presentation. Seminars in Cancer Biology. 2019;66:110–5.
Google Scholar
Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med. 2009;15:267–76.
Google Scholar
Khan A, Bakhru P, Saikolappan S, Das K, Soudani E, Singh CR, et al. An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice. Npj Vaccines. 2019;4:1–19.
Joubert P-E, Werneke SW, de la Calle C, Guivel-Benhassine F, Giodini A, Peduto L, et al. Chikungunya virus-induced autophagy delays caspase-dependent cell death. J Exp Med. 2012;209:1029–47.
Google Scholar
Judith D, Mostowy S, Bourai M, Gangneux N, Lelek M, Lucas-Hourani M, et al. Species-specific impact of the autophagy machinery on Chikungunya virus infection. EMBO Rep. 2013;14:534–44.
Google Scholar
Shoji-Kawata S, Sumpter R, Leveno M, Campbell GR, Zou Z, Kinch L, et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature. 2013;494:201–6.
Google Scholar
Eng KE, Panas MD, Murphy D, Karlsson Hedestam GB, McInerney GM. Accumulation of autophagosomes in Semliki Forest virus-infected cells is dependent on expression of the viral glycoproteins. J Virol. 2012;86:5674–85.
Google Scholar
Maine CJ, Richard G, Spasova DS, Miyake-Stoner SJ, Sparks J, Moise L, et al. Self-replicating RNAs drive protective anti-tumor T cell responses to neoantigen vaccine targets in a combinatorial approach. Mol Ther J Am Soc Gene Ther. 2021;29:1186–98.
Google Scholar
Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. 2014;22:2118–29.
Google Scholar
Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14:1084–7.
Google Scholar
Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D. Nanomaterial delivery systems for mRNA vaccines. Vaccines. 2021;9:65.
Google Scholar
Rennick JJ, Johnston APR, Parton RG. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat Nanotechnol. 2021;16:266–76.
Google Scholar
Dong Y, Love KT, Dorkin JR, Sirirungruang S, Zhang Y, Chen D, et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci USA. 2014;111:3955–60.
Google Scholar
Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther J Am Soc Gene Ther. 2010;18:1357–64.
Google Scholar
Żak MM, Zangi L. Lipid nanoparticles for organ-specific mRNA therapeutic delivery. Pharmaceutics. 2021;13:1675.
Google Scholar
Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev. 2020;154–155:37–63.
Google Scholar
Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun. 2010;34:1–6.
Google Scholar
Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38:1404–13.
Google Scholar
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Disco. 2021;20:101–24.
Google Scholar
Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10:E57.
Google Scholar
Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7:319–34.
Google Scholar
Wang Y, Miao L, Satterlee A, Huang L. Delivery of oligonucleotides with lipid nanoparticles. Adv Drug Deliv Rev. 2015;87:68–80.
Google Scholar
Pepini T, Pulichino A-M, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol Author Choice. 2017;198:4012–24.
Google Scholar
Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078–94.
Google Scholar
Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials. 2010;31:6867–75.
Google Scholar
Ramishetti S, Hazan-Halevy I, Palakuri R, Chatterjee S, Naidu Gonna S, Dammes N, et al. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. Adv Mater. 2020;32:1906128.
Google Scholar
Guevara ML, Persano F, Persano S. Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front Chem. 2020;8:589959.
Google Scholar
Rawal M, Singh A, Amiji MM. Quality-by-design concepts to improve nanotechnology-based drug development. Pharm Res. 2019;36:153.
Google Scholar
Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release J Control Release Soc. 2006;114:100–9.
Google Scholar
Zeng C, Zhang C, Walker PG & Dong Y. Formulation and delivery technologies for mRNA vaccines. Curr Top Microbiol Immunol. 2020. https://doi.org/10.1007/82_2020_217.
Kumar V, Qin J, Jiang Y, Duncan RG, Brigham B, Fishman S, et al. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. Mol Ther – Nucleic Acids. 2014;3:e210.
Google Scholar
Nogueira SS, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer MA, et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl Nano Mater. 2020;3:10634–45.
Google Scholar
Chahal JS, Khan OF, Cooper CL, McPartlan JS, Tsosie JK, Tilley LD, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA. 2016;113:E4133–E4142.
Google Scholar
Blakney AK, Zhu Y, McKay PF, Bouton CR, Yeow J, Tang J, et al. Big is beautiful: enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer. ACS Nano. 2020;14:5711–27.
Google Scholar
Blakney AK, McKay PF, Hu K, Samnuan K, Jain N, Brown A, et al. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. J Controlled Release. 2021;338:201–10.
Google Scholar
Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med. 2009;206:69–78.
Google Scholar
Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity. 2008;29:138–49.
Google Scholar
Longhi MP, Wright K, Lauder SN, Nowell MA, Jones GW, Godkin AJ, et al. Interleukin-6 is crucial for recall of influenza-specific memory CD4+ T cells. PLOS Pathog. 2008;4:e1000006.
Google Scholar
Moderna’s Zika Virus Vaccine Data Supports COVID-19 Vaccine Approach. https://www.biospace.com/article/moderna-s-zika-virus-vaccine-data-supports-covid-19-vaccine-approach/.
Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37:3326–34.
Google Scholar
Moderna Clinical Study Protocol: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older. https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf.
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl J Med. 2020;383:2427–38.
Google Scholar
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–93.
Google Scholar
WHO SAGE Working Group: mRNA vaccines against COVID-19: Pfizer-BioNTech COVID-19 vaccine BNT162b2. https://apps.who.int/iris/bitstream/handle/10665/338096/WHO-2019-nCoV-vaccines-SAGE_evaluation-BNT162b2-2020.1-eng.pdf?sequence=1&isAllowed=y.
Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. Wien Klin Wochenschr. 2021;133:931–41.
Google Scholar
CORAL-BOOST Study Data Presentation. CORAL-BOOST Study Data Present. https://ir.gritstonebio.com/static-files/0904cdf4-3208-4704-b17b-2abf1d48392b.
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate. 2021. https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-28-08-00-00-2304069.
Vaccines Investor Event. Vaccines Invest. Event. 2021. https://www.sanofi.com/en/investors/financial-results-and-events/investor-presentations/Vaccines-Day-2021#.
Aldrich C, Leroux–Roels I, Huang KB, Bica MA, Loeliger E, Schoenborn-Kellenberger O, et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine. 2021;39:1310–8.
Google Scholar
Gritstone Oncology, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K. 2020. https://ir.gritstonebio.com/static-files/9b5ca365-6556-4d32-b0fa-b01b77550ab6.
Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7:38.
Google Scholar
